Vaccine and syringe injection for prevention, immunization and treatment of coronavirus infection (COVID-19, nCoV 2019)

Moderna, a leader in mRNA technology, aims to transform healthcare with nine late-stage programs and an anticipated $4 billion in product sales for 2024, focusing on growth and innovation.

Moderna, Inc., a pioneering biotechnology company in the field of mRNA therapeutics and vaccines, has recently announced an ambitious plan for 2024, focusing on expanding its portfolio of transformative mRNA medicines. At the forefront of Moderna’s strategic vision is a commitment to achieving significant milestones across its nine late-stage programs, reinforcing its position as a leader in mRNA technology.

“In 2023, we achieved $6.7 billion in product sales and resized our COVID-19 manufacturing footprint for the endemic setting. Our team significantly increased our COVID-19 market share to 48% in the U.S,” stated Stéphane Bancel, Chief Executive Officer of Moderna. He added, “We are preparing for the launch of Moderna’s second product, our RSV vaccine. 2024 is going to be an exciting year for the Company with multiple milestones across our nine late-stage programs. Through these product launches, we are focused on returning to sales growth in 2025.”

In a detailed presentation at the 42nd Annual J.P. Morgan Healthcare Conference, Moderna outlined its robust pipeline, including anticipated approvals for its Respiratory Syncytial Virus (RSV) vaccine in adults aged 60 and older. The company also highlighted its next-generation, refrigerator-stable COVID-19 vaccine, currently in a pivotal Phase 3 study, with results expected in the first half of 2024. The seasonal flu vaccine, mRNA-1010, has shown promising results in Phase 3 trials, and Moderna plans to seek regulatory approval in 2024.

Furthermore, Moderna’s pipeline includes a combination vaccine against seasonal flu and COVID-19, with data anticipated in 2024, and a pivotal Phase 3 study of its Cytomegalovirus (CMV) vaccine candidate, a significant step in preventing primary infection in women of childbearing age.

In the oncology sector, Moderna continues to demonstrate the clinical benefits of its Individualized Neoantigen Therapy (INT) program. In partnership with Merck, Phase 3 trials are underway in resected high-risk melanoma and non-small cell lung cancer. “Compared to KEYTRUDA alone, this combination continued to show an improvement in recurrence-free survival, reducing the risk of recurrence or death by 49%, as well as in distant metastasis-free survival, reducing the risk of developing distant metastasis or death by 62%,” Bancel noted.

The company’s financial framework for 2024-2026 projects approximately $4 billion in product sales for 2024, primarily due to COVID-19 vaccine sales and the launch of its RSV vaccine. Moderna anticipates returning to organic sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment.

Moderna’s approach to drug development has been characterized by rapid response and innovation, as evidenced by its development of one of the earliest and most effective COVID-19 vaccines. The company’s diverse pipeline across infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases demonstrates its commitment to leveraging mRNA technology to address a wide range of medical challenges.

As Moderna looks to the future, its focus remains on delivering transformative mRNA medicines to patients worldwide, aiming to make a significant impact on global healthcare. With a strong financial position and a clear strategic vision, Moderna is poised to continue its trajectory of growth and innovation in the coming years.